BioAtla Investor Conference Presentation Deck

BioAtla® is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABs) ● Proprietary technology Broad applicability Spans multiple tumors bicatla ● Two lead CAB-ADC assets in Phase 2 Interim Phase 2 data w/ 3011 supports advancing in multiple sarcoma indications Near-term catalysts ● Diversified and robust pipeline Strategic optionality ● ● ● Strong cash position $219.4MM (at end 1Q22) with runway into 2H24 Sufficient through key clinical milestones BioAtla Overview | Company Confidential 3

View entire presentation